UKKW Expert panel: KDIGO Guidelines on IgAN
Overview
Professor Jonathan Barratt discusses the evolving KDIGO guidelines for IgA nephropathy, emphasising early diagnosis, dual-pathway treatment strategies, and the growing role of therapies like sparsentan, supported by global data and clinical trial insights.
Download the certificate here once you have completed this webinar
Prescribing information and adverse event reporting information:
Filspari®▼(sparsentan): 200 mg , 400 mg
UK-SPT-2500150 (V2.0) | September 2025
Adverse events should be reported. Reporting forms and information for the United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Fresenius Medical Care Renal Pharma, care of Vifor Pharma Ltd.
Tel: +44 1276 853633. E-mail: MedicalInfo_UK@viforpharma.com.
